A Phase 3, Multinational, Double-Blind, Randomized,
Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients
With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve
NASH and Reduce Progression to Cirrhosis and/or Hepatic
Decompensation
Please contact us for more information or to learn if you are eligible to participate.
